Skip to main content

Table 4 Clinical characteristics of the SVR and non-SVR patients

From: LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients

  SVR patients (n = 23)1 Non-SVR patients (n = 18)1 Significance
Age (year) 52.13 ± 7.86 53.78 ± 7.20 p = 0.4530
Gender    p = 0.7020
 Male 14 12  
 Female 9 6  
BMI 23.22 ± 2.98 22.27 ± 2.95 p = 0.3510
ALT (U/L)2 156.59 ± 134.65 80.74 ± 67.90 p = 0.0659
AST (U/L)2 104.59 ± 97.74 65.27 ± 59.63 p = 0.1180
PLT (×109/L)2 138.30 ± 57.34 205.94 ± 102.76 p = 0.0551
AFP 2 2.99 ± 1.23 4.68 ± 2.96 p = 0.0841
HCV RNA (×106 eq/mL)2 1.15 ± 1.60 8.78 ± 9.92 p = 0.0051
FibroScan2 17.16 ± 7.98 13.56 ± 7.15 p = 0.1412
Liver fibrosis assessed by FibroScan    p = 0.2170
 Non-LC 7 9  
 Indeterminate 6 6  
 LC 10 3  
R of LecT-Hepa −0.60 ± 1.48 0.79 ± 1.54 p = 0.0031
R of FIB4 0.38 ± 2.00 0.62 ± 1.76 p = 0.5545
R of APRI 0.01 ± 0.60 0.04 ± 0.28 p = 0.7626
  1. 1)4 of 45 patients were lost to follow-up.
  2. 2)Clinical information was the baseline (0 weeks) information.